The effect of EGFR‐TKIs on survival in advanced non‐small‐cell lung cancer with EGFR mutations: A real‐world study
Abstract Background Few large‐scale studies have been published using real‐world data related to overall survival (OS) improvements in advanced epidermal growth factor receptor (EGFR)‐mutant lung cancer patients; therefore, little is known regarding the characteristics of patients who could benefit...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-03-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.5413 |
| _version_ | 1797866873036996608 |
|---|---|
| author | Xiaoqing Yu Jinfei Si Jingwen Wei Yanling Wang Yan Sun Jianan Jin Xiaoyan Zhang Tonghui Ma Zhengbo Song |
| author_facet | Xiaoqing Yu Jinfei Si Jingwen Wei Yanling Wang Yan Sun Jianan Jin Xiaoyan Zhang Tonghui Ma Zhengbo Song |
| author_sort | Xiaoqing Yu |
| collection | DOAJ |
| description | Abstract Background Few large‐scale studies have been published using real‐world data related to overall survival (OS) improvements in advanced epidermal growth factor receptor (EGFR)‐mutant lung cancer patients; therefore, little is known regarding the characteristics of patients who could benefit most from EGFR‐tyrosine kinase inhibitors (TKIs). Our study aimed to assess whether EGFR‐TKI treatment confers survival benefits among advanced non‐small‐cell lung cancer (NSCLC) patients harboring EGFR mutations in the Chinese population. Patients and Methods A total of 6451 advanced NSCLC patients were diagnosed between January 1, 2013 and June 30, 2019 in Zhejiang Cancer Hospital. Ultimately, 2864 patients with a confirmed EGFR mutation genotype were enrolled in our study. OS was measured from the time of diagnosis of advanced NSCLC until death or last follow‐up. Results Median follow‐up for OS of advanced EGFR‐mutant NSCLC patients was 28.33 months in our study. Patients who received EGFR‐TKIs demonstrated better survival compared to those without EGFR‐TKI treatment (mOS: 29.77 vs. 22.97 months, p < 0.0001). A total of 451 patients switched to third‐generation EGFR‐TKI treatment and obtained a significantly better survival than those who adopted first‐line third‐generation EGFR‐TKIs or those who did not receive third‐generation EGFR‐TKIs after disease progression with first‐ or second‐generation EGFR‐TKI treatment (mOS: 38.0 vs. 32.5 vs. 28.3 months, p < 0.0001). As for EGFR genotypes, patients with exon 19 deletion showed better OS, followed by those with L858R mutation (32.4 vs. 24.83 months, p = 0.0013). NGS versus PCR testing showed no statistical differences with respect to survival outcomes (mOS: 27.5 vs. 27.47 months, p = 0.6745). Conclusion Advanced EGFR‐mutant patients treated with EGFR‐TKIs obtained absolute superior survival in the Chinese population. |
| first_indexed | 2024-04-09T23:32:19Z |
| format | Article |
| id | doaj.art-dc682b5609164fbe9eeb308efedb51af |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-04-09T23:32:19Z |
| publishDate | 2023-03-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-dc682b5609164fbe9eeb308efedb51af2023-03-21T05:20:40ZengWileyCancer Medicine2045-76342023-03-011255630563810.1002/cam4.5413The effect of EGFR‐TKIs on survival in advanced non‐small‐cell lung cancer with EGFR mutations: A real‐world studyXiaoqing Yu0Jinfei Si1Jingwen Wei2Yanling Wang3Yan Sun4Jianan Jin5Xiaoyan Zhang6Tonghui Ma7Zhengbo Song8Department of Clinical Trial The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital) Hangzhou ChinaDepartment of Oncology The Second Clinical Medical College of Zhejiang Chinese Medical University Hangzhou ChinaDepartment of Oncology The First Clinical Medical College of Wenzhou Medical University Wenzhou Zhejiang ChinaDepartment of Clinical Trial The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital) Hangzhou ChinaDepartment of Clinical Trial The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital) Hangzhou ChinaDepartment of Clinical Trial The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital) Hangzhou ChinaDepartment of Translational Medicine, Genetron Health (Beijing) Technology, Co. Ltd. Beijing ChinaDepartment of Translational Medicine, Genetron Health (Beijing) Technology, Co. Ltd. Beijing ChinaDepartment of Clinical Trial The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital) Hangzhou ChinaAbstract Background Few large‐scale studies have been published using real‐world data related to overall survival (OS) improvements in advanced epidermal growth factor receptor (EGFR)‐mutant lung cancer patients; therefore, little is known regarding the characteristics of patients who could benefit most from EGFR‐tyrosine kinase inhibitors (TKIs). Our study aimed to assess whether EGFR‐TKI treatment confers survival benefits among advanced non‐small‐cell lung cancer (NSCLC) patients harboring EGFR mutations in the Chinese population. Patients and Methods A total of 6451 advanced NSCLC patients were diagnosed between January 1, 2013 and June 30, 2019 in Zhejiang Cancer Hospital. Ultimately, 2864 patients with a confirmed EGFR mutation genotype were enrolled in our study. OS was measured from the time of diagnosis of advanced NSCLC until death or last follow‐up. Results Median follow‐up for OS of advanced EGFR‐mutant NSCLC patients was 28.33 months in our study. Patients who received EGFR‐TKIs demonstrated better survival compared to those without EGFR‐TKI treatment (mOS: 29.77 vs. 22.97 months, p < 0.0001). A total of 451 patients switched to third‐generation EGFR‐TKI treatment and obtained a significantly better survival than those who adopted first‐line third‐generation EGFR‐TKIs or those who did not receive third‐generation EGFR‐TKIs after disease progression with first‐ or second‐generation EGFR‐TKI treatment (mOS: 38.0 vs. 32.5 vs. 28.3 months, p < 0.0001). As for EGFR genotypes, patients with exon 19 deletion showed better OS, followed by those with L858R mutation (32.4 vs. 24.83 months, p = 0.0013). NGS versus PCR testing showed no statistical differences with respect to survival outcomes (mOS: 27.5 vs. 27.47 months, p = 0.6745). Conclusion Advanced EGFR‐mutant patients treated with EGFR‐TKIs obtained absolute superior survival in the Chinese population.https://doi.org/10.1002/cam4.5413EGFR‐TKIsnon‐small cell lung cancer (NSCLC)real‐world studysurvival outcome |
| spellingShingle | Xiaoqing Yu Jinfei Si Jingwen Wei Yanling Wang Yan Sun Jianan Jin Xiaoyan Zhang Tonghui Ma Zhengbo Song The effect of EGFR‐TKIs on survival in advanced non‐small‐cell lung cancer with EGFR mutations: A real‐world study Cancer Medicine EGFR‐TKIs non‐small cell lung cancer (NSCLC) real‐world study survival outcome |
| title | The effect of EGFR‐TKIs on survival in advanced non‐small‐cell lung cancer with EGFR mutations: A real‐world study |
| title_full | The effect of EGFR‐TKIs on survival in advanced non‐small‐cell lung cancer with EGFR mutations: A real‐world study |
| title_fullStr | The effect of EGFR‐TKIs on survival in advanced non‐small‐cell lung cancer with EGFR mutations: A real‐world study |
| title_full_unstemmed | The effect of EGFR‐TKIs on survival in advanced non‐small‐cell lung cancer with EGFR mutations: A real‐world study |
| title_short | The effect of EGFR‐TKIs on survival in advanced non‐small‐cell lung cancer with EGFR mutations: A real‐world study |
| title_sort | effect of egfr tkis on survival in advanced non small cell lung cancer with egfr mutations a real world study |
| topic | EGFR‐TKIs non‐small cell lung cancer (NSCLC) real‐world study survival outcome |
| url | https://doi.org/10.1002/cam4.5413 |
| work_keys_str_mv | AT xiaoqingyu theeffectofegfrtkisonsurvivalinadvancednonsmallcelllungcancerwithegfrmutationsarealworldstudy AT jinfeisi theeffectofegfrtkisonsurvivalinadvancednonsmallcelllungcancerwithegfrmutationsarealworldstudy AT jingwenwei theeffectofegfrtkisonsurvivalinadvancednonsmallcelllungcancerwithegfrmutationsarealworldstudy AT yanlingwang theeffectofegfrtkisonsurvivalinadvancednonsmallcelllungcancerwithegfrmutationsarealworldstudy AT yansun theeffectofegfrtkisonsurvivalinadvancednonsmallcelllungcancerwithegfrmutationsarealworldstudy AT jiananjin theeffectofegfrtkisonsurvivalinadvancednonsmallcelllungcancerwithegfrmutationsarealworldstudy AT xiaoyanzhang theeffectofegfrtkisonsurvivalinadvancednonsmallcelllungcancerwithegfrmutationsarealworldstudy AT tonghuima theeffectofegfrtkisonsurvivalinadvancednonsmallcelllungcancerwithegfrmutationsarealworldstudy AT zhengbosong theeffectofegfrtkisonsurvivalinadvancednonsmallcelllungcancerwithegfrmutationsarealworldstudy AT xiaoqingyu effectofegfrtkisonsurvivalinadvancednonsmallcelllungcancerwithegfrmutationsarealworldstudy AT jinfeisi effectofegfrtkisonsurvivalinadvancednonsmallcelllungcancerwithegfrmutationsarealworldstudy AT jingwenwei effectofegfrtkisonsurvivalinadvancednonsmallcelllungcancerwithegfrmutationsarealworldstudy AT yanlingwang effectofegfrtkisonsurvivalinadvancednonsmallcelllungcancerwithegfrmutationsarealworldstudy AT yansun effectofegfrtkisonsurvivalinadvancednonsmallcelllungcancerwithegfrmutationsarealworldstudy AT jiananjin effectofegfrtkisonsurvivalinadvancednonsmallcelllungcancerwithegfrmutationsarealworldstudy AT xiaoyanzhang effectofegfrtkisonsurvivalinadvancednonsmallcelllungcancerwithegfrmutationsarealworldstudy AT tonghuima effectofegfrtkisonsurvivalinadvancednonsmallcelllungcancerwithegfrmutationsarealworldstudy AT zhengbosong effectofegfrtkisonsurvivalinadvancednonsmallcelllungcancerwithegfrmutationsarealworldstudy |